StockNews.AI
SLNO
StockNews.AI
13 hrs

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

1. Pomerantz LLP is investigating potential securities fraud at Soleno Therapeutics. 2. Soleno's only product, Vykat XR, has been criticized as overpriced and unsafe. 3. Following negative reports, SLNO's stock price declined by 7.41%. 4. Class-action claims may affect investor confidence in Soleno's management. 5. Investors are urged to contact Pomerantz for participation in the investigation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The stock price's significant drop indicates market distress linked to fraud allegations and product safety concerns, reminiscent of past cases like Valeant Pharmaceuticals' downfall.

How important is it?

The investigation and class action could have deep implications for Soleno's credibility and financial standing.

Why Short Term?

The immediate financial market reaction shows a high level of volatility due to current events, but it could stabilize pending investigation outcomes.

Related Companies

VRXTGTXNTEST
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 15, 2025, Scorpion Capital (“Scorpion”) published a report that described Soleno’s only product, Vykat XR, as overpriced and potentially unsafe for children. Following publication of the Scorpion report, Soleno’s stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News